Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-221634
Filing Date
2026-05-13
Accepted
2026-05-13 16:12:18
Documents
71
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acrv-20260331.htm   iXBRL 10-Q 1534869
2 EX-31.1 acrv-ex31_1.htm EX-31.1 17617
3 EX-31.2 acrv-ex31_2.htm EX-31.2 17574
4 EX-32.1 acrv-ex32_1.htm EX-32.1 11281
5 EX-32.2 acrv-ex32_2.htm EX-32.2 11242
  Complete submission text file 0001193125-26-221634.txt   7200371

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acrv-20260331.xsd EX-101.SCH 1115972
75 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20260331_htm.xml XML 1191094
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41551 | Film No.: 26973386
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)